- Home
- FENC vs DSGN Comparison
FENC vs DSGN Comparison
Compare FENC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- DSGN
- Stock Information
- Founded
- FENC 1996
- DSGN 2017
- Country
- FENC United States
- DSGN United States
- Employees
- FENC N/A
- DSGN N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- DSGN Health Care
- Exchange
- FENC Nasdaq
- DSGN Nasdaq
- Market Cap
- FENC 234.9M
- DSGN 208.9M
- IPO Year
- FENC 2001
- DSGN 2021
- Fundamental
- Price
- FENC $8.67
- DSGN $5.83
- Analyst Decision
- FENC Strong Buy
- DSGN
- Analyst Count
- FENC 2
- DSGN 0
- Target Price
- FENC $13.50
- DSGN N/A
- AVG Volume (30 Days)
- FENC 77.1K
- DSGN 201.9K
- Earning Date
- FENC 11-06-2025
- DSGN 11-06-2025
- Dividend Yield
- FENC N/A
- DSGN N/A
- EPS Growth
- FENC N/A
- DSGN N/A
- EPS
- FENC N/A
- DSGN N/A
- Revenue
- FENC $33,302,000.00
- DSGN N/A
- Revenue This Year
- FENC $0.18
- DSGN N/A
- Revenue Next Year
- FENC $52.59
- DSGN N/A
- P/E Ratio
- FENC N/A
- DSGN N/A
- Revenue Growth
- FENC N/A
- DSGN N/A
- 52 Week Low
- FENC $3.96
- DSGN $2.60
- 52 Week High
- FENC $9.92
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- FENC 47.99
- DSGN 44.21
- Support Level
- FENC $8.24
- DSGN $5.67
- Resistance Level
- FENC $8.90
- DSGN $7.21
- Average True Range (ATR)
- FENC 0.41
- DSGN 0.57
- MACD
- FENC -0.10
- DSGN -0.14
- Stochastic Oscillator
- FENC 29.24
- DSGN 7.14
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.